Anavex Life Sciences Corp.

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1 in Phase 3

Quick facts

Phase 3 pipeline

ANAVEX2-73 · Neurology
ANAVEX2-73 is a sigma-1 receptor agonist that activates neuroprotective pathways to treat neurodegenerative diseases.

Phase 2 pipeline

ANAVEX2-73 Intravenous · Neurology
ANAVEX2-73 is a small molecule that modulates sigma-1 receptors and muscarinic acetylcholine receptors, which may have neuroprotective effects.
ANAVEX2-73 oral liquid · Neurology
ANAVEX2-73 is an oral liquid formulation of a sigma-1 receptor agonist.
ANAVEX3-71 oral capsules · Neurology
ANAVEX3-71 is a sigma-1 receptor agonist that modulates neuroprotective and neuroinflammatory pathways in the central nervous system.
Mid dose ANAVEX2-73

Phase 1 pipeline

ANAVEX3-71

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Anavex Life Sciences Corp.

What is Anavex Life Sciences Corp.'s pipeline?

Anavex Life Sciences Corp. has 1 drugs in Phase 3, 4 in Phase 2, 1 in Phase 1. Late-stage candidates include ANAVEX2-73.

Sector hub: All tracked pharma companies